Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Nieuwe tool biedt inzicht in gevolgen borstkanker tot 14 jaar na diagnose
feb 2022 | Borstkanker